不清淋，而是用干扰素IFNa

《Effective TIL therapy for patients with checkpoint-resistant melanoma without lymphodepleting regimens requires interferon-alpha》

+ V. W; P' Z) `Purpose: Melanoma patients progressing despite immune checkpoint blockade (ICB) may benefit from adoptive transfer of tumor infiltrating lymphocytes (TIL).
Patients and methods: We investigated the impact of a pegylated interferon-alpha (IFNa) conditioning and support regimen on the safety and efficacy of TIL plus Nivolumab (NCT03638375). ICB-resistant stage III/IV melanoma patients were treated with TIL plus Nivolumab without (n=9) or with (n=25) IFNa.
# b2 H% Y8 o# a/ K2 K9 IResults: The treatment was safe, side effects include IFNa-induced lymphopenia (16%) and neutropenia (12%). No febrile neutropenia and no > grade 4 adverse events were observed. Disease control was obtained in 11.1% (95% CI: -14.5%-36.7%) of the patients treated without and in 41.7% (95% CI: 20.4%-62.9%) of the patients treated with IFNa, clearly suggesting the need for IFNa support. IFNa treatment strongly reduced the numbers of circulating leukocytes and neutrophils, more consistently in therapy responders. No differences were observed in the phenotype and dose of TIL administered.
3 ~! q; ^8 A& ?( |Conclusion: Taken together, our low-toxicity therapy comprising TIL, Nivolumab and IFNa is safe, shows evidence of clinical activity, and may be particularly suitable for more frail patients who are less able to tolerate lymphodepletion and high-dose interleukin-2 regimens.